Welcome to our dedicated page for Silvaco Group SEC filings (Ticker: SVCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Silvaco Group, Inc. (SVCO) SEC filings page brings together the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed technology issuer in the Software - Application industry, Silvaco uses SEC reports to provide detail on its TCAD, EDA, and semiconductor IP business, financial performance, acquisitions, and corporate governance.
Investors can review current and historical Forms 8-K in which Silvaco reports material events. Recent 8-K filings describe quarterly financial results, the acquisition of Mixel Group, Inc., leadership transitions in the Chief Executive Officer and Chief Financial Officer roles, and a restructuring program involving cost-savings initiatives, reductions in force, and planned site closures. These filings often reference accompanying press releases and may include summaries of key agreements, such as stock purchase agreements, employment contracts, and separation agreements.
In addition to event-driven reports, users can access Silvaco’s annual reports on Form 10-K and quarterly reports on Form 10-Q when available. These periodic filings typically provide segment information for TCAD, EDA, and SIP revenue, risk factor discussions related to semiconductor and photonics markets, and management’s analysis of operating trends. They also contain information on the company’s global footprint, which includes a headquarters in Santa Clara, California, and offices across North America, Europe, Egypt, Brazil, China, Japan, Korea, Singapore, Vietnam, and Taiwan.
Form 4 and related insider transaction reports, when filed, allow readers to track equity awards and share transactions by Silvaco’s directors and executive officers, complementing the compensation and governance details in proxy statements. Stock Titan’s platform enhances these documents with AI-powered summaries that highlight key points from lengthy 10-K, 10-Q, and 8-K filings, helping users quickly identify items such as restructuring charges, acquisition terms, or changes in leadership. Real-time updates from EDGAR ensure that new SVCO filings appear promptly, while AI-generated insights can reduce the time required to interpret complex regulatory language.
Silvaco Group, Inc. announced that Christopher Zegarelli will join as Chief Financial Officer effective September 15, 2025. His base salary is $450,000 and he is eligible for a $400,000 sign-on bonus paid in two $200,000 installments, the first payable within 30 days of the start date and subject to repayment if he voluntarily resigns or is terminated for cause before January 1, 2027. The second installment is contingent on achieving fiscal 2026 revenue and profit targets at or above 100% of plan and continued service through December 31, 2026. He is eligible for an annual incentive target equal to 60% of base salary, prorated for 2025, with payment based on company-wide performance and at the Board's discretion. He will receive RSUs equal to $2,300,000 in value with 1/4 vesting after one year and the balance vesting quarterly to fully vest at year four. He is eligible for the Executive Severance Plan and an indemnification agreement. The company disclosed the appointment via a press release furnished as Exhibit 99.1.
Silvaco Group, Inc. reported a CEO transition and related compensation arrangements. Dr. Babak A. Taheri stepped down as CEO and director, effective August 19, 2025, and entered a Separation Agreement providing severance and other benefits. Under that agreement he will receive aggregate cash severance of $975,484 (equal to 18 months' base salary plus pro‑rata target bonus), COBRA health benefit payments for 15 months, accelerated vesting of 126,161 unvested time‑based restricted stock units, 12 months of car lease payments totaling $12,000, and payment of a $20,000 life insurance premium. The agreement also preserves confidentiality, non‑disparagement and non‑solicit covenants and includes a release of claims.
The Board appointed Dr. Walden C. Rhines as CEO, effective August 19, 2025, and the company entered an employment agreement through March 31, 2027. Dr. Rhines will receive an annual base salary of $160,000 and may receive performance‑based restricted stock unit grants with grant‑date fair values ranging from $100,000 up to an aggregate of $6,252,636, vesting upon achievement of specified VWAP trading thresholds and continued employment through the Term. If terminated under certain conditions before or at the end of the Term, Dr. Rhines may be eligible for a lump sum severance ranging from $500,000 to $1,000,000 and accelerated vesting of PRSUs, subject to a release and covenant compliance.
Form 4 summary: Taheri Babak A., listed as Chief Executive Officer and Director of Silvaco Group, Inc. (SVCO), reported a change in beneficial ownership on 08/13/2025. The filing shows a disposition of 9,155 shares of common stock at a price of $4.65 per share under transaction code F. The filing explains these shares were withheld by the issuer to satisfy tax withholding obligations related to the vesting of restricted stock units. After the transaction, the reporting person beneficially owned 773,157 shares on a direct basis. The form was signed by Candace Jackson as attorney-in-fact on 08/14/2025.